利培酮市场 - 全球产业规模、份额、趋势、机会和预测，按给药途径、按应用、按最终用户、按地区、按竞争进行细分，2020-2030F

2024 年全球利培酮市场价值为 6,057.5 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 5.10%。 全球利培酮市场是製药业的关键领域，其驱动因素是对有效治疗精神疾病的需求。利培酮是一种抗精神病药物，在治疗精神分裂症、躁郁症和某些情绪障碍等疾病方面发挥重要作用。

主要市场驱动因素

精神疾病盛行率上升

主要市场挑战

监管障碍和安全问题

主要市场趋势

更重视心理健康意识和治疗

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：利培酮市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依给药途径（注射、口服、肠胃外）
  • 按应用（精神分裂症、躁郁症、自闭症相关易怒症、其他）
  • 按最终使用者（医院、家庭护理、专科诊所、门诊手术中心等）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美利培酮市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲利培酮市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区利培酮市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美利培酮市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲利培酮市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球利培酮市场：SWOT 分析

第 14 章：波特五力分析

第 15 章：竞争格局

• Otsuka Pharmaceutical Co., Ltd
• AbbVie Inc
• Dr. Reddy's Laboratories Ltd
• Pfizer Inc
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Viatris Inc
• Novartis AG
• Lupin Limited

第 16 章：策略建议

第17章 调査会社について・免责事项

Global Risperidone Market was valued at USD 605.75 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.10% through 2030. The global Risperidone market is a crucial segment of the pharmaceutical industry, driven by the demand for effective treatments of psychiatric disorders. Risperidone, an antipsychotic medication, plays a central role in managing conditions like schizophrenia, bipolar disorder, and certain mood disorders.

Key Market Drivers

Rising Prevalence of Mental Health Disorders

The rising prevalence of mental health disorders is a significant driver of the global Risperidone market, influencing demand, market expansion, and investment in mental health treatments. Risperidone, an antipsychotic medication primarily used to treat conditions such as schizophrenia, bipolar disorder, and irritability associated with autism, has seen increased adoption due to the growing burden of mental health issues worldwide. Mental health disorders, including schizophrenia, bipolar disorder, and autism spectrum disorders, are becoming more prevalent globally due to factors such as urbanization, lifestyle changes, stress, and greater awareness and diagnosis of these conditions. According to the World Health Organization (WHO), Approximately 1 in 4 of the global population will experience mental or neurological disorders at some stage in their lives. Currently, around 450 million individuals are affected by these conditions, making mental health disorders one of the primary contributors to ill-health and disability worldwide. Increased awareness campaigns and educational initiatives by governments, healthcare organizations, and advocacy groups have reduced the stigma surrounding mental health issues. As a result, more individuals are seeking diagnosis and treatment, leading to higher prescription rates of medications like Risperidone. This cultural shift has expanded the addressable market for antipsychotic drugs, driving growth in the Risperidone market.

Key Market Challenges

Regulatory Hurdles and Safety Concerns

The pharmaceutical industry operates within a heavily regulated framework, and Risperidone is no exception. Risperidone, like all medications, undergoes rigorous safety evaluations. Concerns about side effects, particularly metabolic and neurological issues, have led to increased scrutiny. Regulatory bodies often require pharmaceutical companies to update safety labels or provide additional warnings. As Risperidone loses patent protection in various regions, generic versions become available. Generic competition can lead to price erosion, reducing the revenue potential for branded Risperidone. These dynamic challenges market growth, as lower prices may affect profitability.

Key Market Trends

Increasing Focus on Mental Health Awareness and Treatment

Governments, international organizations, and healthcare advocacy groups have launched global mental health initiatives. These programs aim to raise awareness, reduce stigma, and improve access to mental health treatment. As a result, more individuals are seeking help for psychiatric disorders, driving the demand for medications like Risperidone. The integration of telehealth and digital mental health services has expanded access to psychiatric care. Remote consultations and telemedicine platforms facilitate diagnosis and treatment, including the prescription of Risperidone. This trend has gained further prominence during the COVID-19 pandemic. A shift towards community-based mental health services ensures that individuals have easier access to care. This trend promotes early diagnosis and treatment, leading to increased utilization of psychiatric medications like Risperidone.

Key Market Players

• Otsuka Pharmaceutical Co., Ltd
• AbbVie Inc
• Dr. Reddy's Laboratories Ltd
• Pfizer Inc
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Viatris Inc
• Novartis AG
• Lupin Limited

Report Scope:

In this report, the Global Risperidone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Risperidone Market, By Route Of Administration:

• Injectable
• Oral
• Parenteral

Risperidone Market, By Application:

• Schizophrenia
• Bipolar Disorder
• Irritability Associated with Autistic Disorder
• Others

Risperidone Market, By End-Users:

• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Risperidone Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Risperidone Market.

Available Customizations:

Global Risperidone market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Risperidone Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route Of Administration (Injectable, Oral, Parenteral)
  • 5.2.2. By Application (Schizophrenia, Bipolar Disorder, Irritability Associated with Autistic Disorder, Others)
  • 5.2.3. By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Risperidone Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Risperidone Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Risperidone Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Risperidone Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Risperidone Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Risperidone Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Risperidone Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Risperidone Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Risperidone Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Risperidone Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Risperidone Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Risperidone Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Risperidone Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Risperidone Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Risperidone Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Risperidone Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Risperidone Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Risperidone Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Risperidone Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Risperidone Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Risperidone Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Risperidone Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Risperidone Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Risperidone Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Risperidone Market: SWOT Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

• 15.1. Otsuka Pharmaceutical Co., Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. AbbVie Inc
• 15.3. Dr. Reddy's Laboratories Ltd
• 15.4. Pfizer Inc
• 15.5. Endo International plc
• 15.6. Teva Pharmaceutical Industries Ltd
• 15.7. Sun Pharmaceutical Industries Ltd
• 15.8. Viatris Inc
• 15.9. Novartis AG
• 15.10.Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer